Portal Hypertension

Top Story

VIDEO: Liver disease topics discussed at DDW include HCV, NAFLD, statins

May 12, 2017

CHICAGO — In this exclusive video from Digestive Disease Week, Norah Terrault, MD, MPH, discusses the topics reviewed during a press conference involving several experts attending the meeting. Some of the key features of the meeting included new developments for treating hepatitis C, new data emerging on difficult to treat groups such as persons who inject drugs, and the industry’s focus on fatty liver disease.

In the Journals

'Acute on chronic GI bleeding' identified as a distinct syndrome linked to cirrhosis, portal hypertension

April 24, 2017
Researchers have identified a unique GI bleeding syndrome associated with cirrhosis and portal hypertension, which they call “acute on chronic GI bleeding.”…
In the Journals

Noninvasive tests predict portal hypertension, varices in cirrhosis

November 9, 2016
Recent findings suggest noninvasive tests can be used to identify patients with compensated liver disease at high risk for clinically significant portal hypertension and…
FDA News

FDA grants orphan drug designation to BIV201 for most ascites treatments

September 14, 2016
The FDA granted BioVie Inc. orphan drug designation for BIV201 for the treatment of ascites in all instances except those caused by cancer, according to the company…
CME

HCV Updates and Case Challenges for the Rapidly Changing Landscape

This activity is supported by an educational grant from Merck & Co., Inc.

In the past few years, significant progress has been made in the treatment of chronic hepatitis C virus (HCV). Highly…
More »
GI Bookshelf

Chapter 54: Gastrointestinal Bleeding and a Purpuric Rash

From Complicated Cases in GI
More »
Featured
International Liver Congress

International Liver Congress

Video
Meeting News

VIDEO: Liver disease topics discussed at DDW include HCV, NAFLD, statins

May 12, 2017
More »
Meeting NewsVideo

VIDEO: Liver disease topics discussed at DDW include HCV, NAFLD, statins

May 12, 2017
CHICAGO — In this exclusive video from Digestive Disease Week, Norah Terrault, MD, MPH, discusses the topics reviewed during a press…

In the Journals

'Acute on chronic GI bleeding' identified as a distinct syndrome linked to cirrhosis, portal hypertension

April 24, 2017
Researchers have identified a unique GI bleeding syndrome associated with cirrhosis and portal hypertension, which they call “acute on chronic…

In the Journals

Noninvasive tests predict portal hypertension, varices in cirrhosis

November 9, 2016
Recent findings suggest noninvasive tests can be used to identify patients with compensated liver disease at high risk for clinically significant…

FDA News

FDA grants orphan drug designation to BIV201 for most ascites treatments

September 14, 2016
The FDA granted BioVie Inc. orphan drug designation for BIV201 for the treatment of ascites in all instances except those caused by cancer, according…

In the Journals

New MRI model estimates portal pressure as well as HVPG

August 12, 2016
A combined model of non-invasive quantitative MRI measures of liver spine-echo echo planar imaging longitudinal relaxation time and splenic artery…

In the Journals

New hepatic venous outflow tract obstruction prognostic scores superior in India

July 15, 2016
At the All India Institute of Medical Sciences, new prognostic scores developed for hepatic venous outflow tract obstruction were superior to other…

In the Journals

TIPS safe, effective in patients with idiopathic noncirrhotic portal hypertension

July 14, 2016
Transjugular intrahepatic portosystemic shunts were safe and effective in treating the complications of patients with idiopathic noncirrhotic portal…

In the Journals

Beta-blockers may prevent decompensated cirrhosis for portal hypertension

December 17, 2015
New data published in Hepatology showed that beta-blockers lowered portal pressure in patients with clinically significant portal hypertension…

In the Journals

IPVDs decrease survival in portopulmonary hypertension

December 8, 2015
Intrapulmonary vascular dilatations occurred more commonly in patients with portopulmonary hypertension and were associated with decreased overall…

Meeting News Coverage

Emricasan reduces portal pressure in patients with cirrhosis

December 1, 2015
SAN FRANCISCO — A 28-day oral course of therapy with emricasan, a pan-caspase inhibitor, reduced portal pressure in patients with compensated…

More Headlines »
Advertisement
Advertisement